共 50 条
- [1] CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1 [J]. Journal of Experimental & Clinical Cancer Research, 41
- [4] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer [J]. Clinical Pharmacokinetics, 2018, 57 : 427 - 437
- [6] Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
- [7] Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5223 - 5237
- [8] CDK4/6 inhibitors in breast cancer: a role in triple-negative disease? [J]. LANCET ONCOLOGY, 2019, 20 (11): : 1479 - 1481
- [9] Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer [J]. Journal of Experimental & Clinical Cancer Research, 40